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Pleurodesis of malignant pleural effusion provides for a substantially better quality of life compared to onging 
exudation with the need for repeated evacuation of fluid. Successful pleurodesis leads to permanent cessation of 
fluid production as a result of the formation of fibrous adhesion between the lung and costal pleura which in theory, 
however, might restrict lung mobility. In patients with poor lung function, or with need for bilateral pleurodesis, the 
apprehension of further impairment of lung function often arises. The aim of this study was to evaluate the effects 
of pleurodesis on lung function. Therefore 10 patients with malignant pleurisy with very limited tumour were 
investigated. They were without radiological signs of tumour infiltration in the lung parenchyma, without visible 
tumour growth in the pleural space during thoracoscopy and had undergone a successful one-sided pleurodesis. 
Respiratory function tests were performed at different times, l-102 months after pleurodesis. The assessment 
consisted of: static and dynamic spirometry, exercise testing with blood gas determination and radiospirometry. 
Spirometric values were slightly low, but in general within the reference limits. Blood gas determination showed 
no signs of alveolar hypoventilation. Radiospirometry showed a slight attenuation of activity in the treated lung but 
similar turnover of gas of the treated M. the untreated side. The study showed that pleurodesis in malignant pleurisy 
has only minor impact on respiratory function. 
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Introduction 
Metastatic or direct spread of malignant tumours to the 
pleura may cause recurrent large pleural exudates, prompt- 
ing repeated thoracocenteses. The most common primary 
tumours are lung and breast carcinoma (1). The first 
measure in a substantial malignant pleural effusion is 
thoracocentesis, which gives temporary relief of symptoms. 
However, recurrent thoracocenteses lead to a risk of fibrin 
and/or malignant cells covering the lung surface, thereby 
restricting expansion of the lung (2), cause loss of protein 
and blood cells and also constitute an unpleasant and 
terrifying reminder of the disease, in addition to the cost of 
the medical care. Thus, if thoracocentesis has to be 
repeated, pleurodesis is indicated. Successful treatment 
leads to permanent inhibition of fluid production with 
minor pleural thickening, relief of dyspnoea, cough and 
psychological relief. Many agents have been used to achieve 
pleurodesis. Currently the most commonly used agent 
seems to be sterilized talc (3). However, in many European 
centres, including ours, atabrine (Quinacrine, Vipor Che- 
Paper received 24 March 1999 and accepted in revised form 9 July 
1999. 
Correspondence should be addressed to: Valiant Ukale, Div. of 
Respiratory Medicine, Dept of Medicine, Karolinska Hospital, S- 
171 76 Stockholm. Sweden. Fax: +46 8 31 27 05. 
mical, Baroda, Italy) has been used with good results and 
minor side effects for at least 20 yr (4-7). Pleurodesis is 
achieved by an inflammation, causing fibrotic reaction and 
adhesion of the pleurae (1,8). The influence of the 
procedure on lung function in malignant pleural disease is 
difficult to evaluate. Long-term follow-up is rarely possible 
because of the progressive nature of the underlying disease. 
The aim of this study was to evaluate the effects of 
pleurodesis per se on lung function measured by dynamic 
and static spirometry, blood gases at rest and during 
exercise and by ventilation/perfusion scintigraphy. 
Methods 
The criteria for inclusion in the study were: 1) Recurrent 
one-sided malignant pleurisy, 2) no signs of tumour growth 
or bulk in the lung parenchyma on chest radiography at the 
time of admission nor at the time of functional assessment, 
3) no visible tumour growth in the pleural space on 
thoracoscopy, 4) successful pleurodesis (diminishing of 
pleural fluid production to less than 50 ml 24 h-’ before 
chest tube removal and no signs of recurrence with need for 
further evacuation of fluid), 5) a uniform circumferential 
thickening of the pleura as determined with computerized 
tomography of less than 1 cm so as to optimize the 
conditions for radiospirometry and 6) informed consent by 
the patient. 
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PATIENTS 
The case histories of all patients who had undergone 
thoracoscopy because of recurrent effusion from January 
1986 and June 1996 were scrutinized. Out of a total of 733 
cases, 10 patients were in relatively good health and fulfilled 
the criteria for inclusion and were able and willing to 
participate in the study. 
There were three males and seven females, mean age 
66 f 13 years (range 42-85 years). The time from pleurod- 
esis to functional assessment varied from l-102 months 
with a median of 12 months. The sites of primary tumour 
were the breast in four (patients no. 2,4,6 and 7), the lung in 
two (patients no. 8 and 9) both small cell lung carcinoma, 
one patient had a mesothelioma (patient no. 3), and one 
each from the following organs: ventricle (patient no. 5), 
lymph nodes (patient no.1, Mb Hodgkin) and ovary 
(patient no.10). There were five smokers, three ex-smokers 
and two patients who had never smoked. None of the 
patients had clinical signs of extrapulmonary ventilatory 
impairment, or a past history of chronic bronchitis or 
asthma. The study was approved by the local ethics 
committee and the isotope committee. 
THE PROCEDURE OF PLEURODESIS 
The procedure of pleurodesis has been previously described 
(47). After thoracoscopy, a drainage tube of 20 mm was 
inserted between the ribs and when the lung had expanded 
on chest radiography, 600 mg of Quinacrine dispersed in 20 
ml saline was instilled intrapleurally. The chest tube was re- 
moved when the fluid production was less than 50 ml 24 h-l. 
This procedure lasted 4-7 days. 
FUNCTIONAL TESTS 
Patients were investigated l-102 months after pleurodesis, 
when judged to be in good general health and the 
underlying malignancy was under control. 
1. Spirometry: Static and dynamic spirometry were 
performed using a Pulmonary Function 2400 spirometer 
(Sensor Medics, Bilthoven, The Netherlands) connected to 
an IBM Computer 486 DX2/SP. The static lung volumes, 
i.e. total lung capacity (TLC) and residual volume (RV), 
were determined with helium dilution. Slow and forced vital 
capacity (VC and FVC) and the forced expired volume in 
1 set (FEVi,e) were measured and the percentage of FEVl/ 
VC (FEV%) was calculated. Flow-volume curves were 
plotted from the best of three forced expirations. The 
maximal voluntary ventilation was determined at a 
respiratory rate of 40 min-’ (MW,,). Reference values 
according to the European Coal and Steel Community were 
used (9). 
2. Exercise test: Patients exercised sitting on a bicycle 
ergometer, starting at a work load of 30 W which was 
increased by 10 W every minute to a symptom limited 
maximum. Chest pain, dyspnoea and leg fatigue were 
assessed according to Borg’s scale (10). 
3. Blood gases at rest and exercise: Arterial blood samples 
were withdrawn from an indwelling short plastic cannula in 
the radial artery, for determination of arterial oxygen 
tension (PaOz), arterial carbon dioxide tension (PaCO& 
pH and arterial oxygen saturation (SaO,). Samples were 
anti-coagulated with heparin sodium and analysed imme- 
diately. PaOz, SaOZ, PaC02 and pH were measured with a 
blood gas analyser (IL BGM 312, Instrumentation La- 
boratories Inc., Lexington, U.S.A). A sample was taken at 
rest, at maximal work load and 10 min after exercise. In one 
patient it was not possible to insert the arterial cannula. 
SaOZ was then measured with a pulse oximeter (Nellcor 
Inc., Hayward, Ca., U.S.A.) 
REGIONAL LUNG FUNCTION 
Regional lung function was measured using the method of 
radiospirometry (11). Lung perfusion was imaged following 
intravenous injection of 74 MBq 99m-technetium (99mTc) 
macroaggregated albumin. A dorsal image of the distribu- 
tion was acquired on a gamma-camera system (Gamma- 
camera: SX300, Picker International, Cleveland, Ohio, 
U.S.A.; PDP11/73 Gamma 11 computer: Nuclear Diag- 
nostics, Stockholm, Sweden). Without changing the posi- 
tion of the patient with respect to the gamma-camera, the 
patient then breathed into a closed spirometer and a bolus 
of 1000 MBq 133-Xenon (133Xe) gas was introduced into 
the inhalation side of the spirometer. Images were acquired 
for 30 set from the start of inhalation. Approximately 5 min 
later, when ‘33Xe had equilibrated in the lungs, the 
spirometer was opened to the air and 133Xe gradually 
‘washed-out’ from the system at a rate depending on tidal 
volume and degree of gas retention in the lungs. Images 
were acquired for 5 min from the start of wash-out. 
All 133Xe images were corrected for down scatter from 
99mT~ in the 133Xe energy window and for activity in the 
chest wall (background). An image representing regional 
ventilation was generated by adding the images from the 
start of 133Xe inhalation to give a total of 300 000 counts. 
From the perfusion image data, the total counts in each 
lung were summed and expressed as a percentage of the 
total counts in both lungs (relative perfusion Q). Relative 
ventilation (V%) for each lung was calculated in a similar 
manner from the ventilation image data. The values 
obtained were then used to calculate a V/Q ratio for each 
lung. The time (T& taken for half the 133Xe gas present at 
the start of wash-out, to disappear from each lung was also 
calculated. TilZ was calculated from the area (A) below the 
wash-out curve and its initial height (H) according to the 
formula ln2 x A/H. 
STATISTICAL ANALYSIS 
Group data are expressed as means + 1 standard deviation 
unless otherwise stated. The Mann-Whitney U-test for 
unpaired observations was used for comparison of ventila- 
tion/perfusion ratios and turn-over of gas between treated 
and untreated lungs. 
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TABLE 1. Spirometric values in 10 patients l-102 months after succesful one-side pleurodesis [Percentage of predicted values 
(Mean + SD)] 
Patient number TLC% RV% VC% FVC% FEV, % FEV% MVV‘$Q% 
1’ 82 89 82 84 83 101 82 
2 84 87 87 80 67 80 69 
3 91 72 112 108 104 92 82 
4 80 87 80 81 69 90 66 
5 101 107 88 92 68 
6 98 99 102 98 82 80 77 
7 82 74 77 72 68 
8 81 91 80 79 76 93 70 
9 132 185 101 106 87 89 71 
10 124 148 115 114 104 95 107 
Total 8 8 10 10 10 10 10 
Mean 96.5 107.25 94.2 93.1 83.7 88.4 76 
SD 20.45 38.61 13.56 14.93 12.72 8.58 12.35 
For abbreviations see text. 
Results 
SPIROMETRY 
Most of the values for volume and flow were between 80- 
90% of predicted values when adjusted for age and gender 
of the patients (Table 1). Three patients (patients no. 4, 7 
and 8) underwent lung function test 56 weeks after 
pleurodesis. Their spirometric values tended to be slightly 
lower compared to the patients who performed the lung 
function test many months to years after pleurodesis. Two 
patients (patients no. 5 and 7) did not perform static 
spirometry. Their vital capacities were within the normal 
range. Their FEVJVC (FEV %) were 92% and 72 % of 
predicted, respectively. 
EXERCISE TEST 
The patients managed from 60 W to 150 W on the bicycle 
with a mean of 95+26 W. The majority of the patients 
stopped exercising because of dyspnoea and/or leg fatigue. 
BLOOD GASES 
PaOz and PaCOz at rest were within normal limits 
11.1 k 1.4 kPa and 4.9 kO.3 kPa respectively. Mean Sa02 
was 96.7 + 1.4 %. During and after exercise. Pa02 increased 
normally and conversely, PaC02 tended to decrease (Fig. 1). 
RADIOSPIROMETRY 
There were slight reductions of activity in the treated lungs, 
both in the perfusion and ventilation studies. However, 
when ventilation/perfusioq ratios were calculated there was 
no significant difference between the lungs (Table 2). The 
turn over of xenon for each lung was expressed in terms 
I I I 
Rest Exercise Post exercise 
FIG 1. Blood gases at rest, during and 10 min after 
excercise in 9 patients after successful one-sided 
pleurodesis. Mean + SD 
of the wash-out curves obtained at radiospirometry. 
The wash-out (T~,z ) did not differ significantly between 
the treated and untreated lungs (Fig. 2). Data from nine 
patients were used in the analysis because one patient 
(patient no. 7) was not able to complete the procedure. 
Discussion 
The main observation of this study was that pleurodesis per 
se in malignant pleurisy without visible tumour in the lung 
parenchyma and in the pleural space has only a minor 
limiting influence on gas turn-over of the affected lung and 
on the total respiratory function. Viskum et al. reported a 
similar result after talc pleurodesis for spontaneous 
pneumothorax (12), confirming a previous report by 
PLEURODE~I~ AND RESPIRATORY ACTION 901 
TJBLE 2. Relative distribution of perfusion, ventilation and volume in 9 patients after a succesful one-sided pleurodesis. 
Patient number Treated side Q%L Q%R V%L V%R V%L V%R wt ml 
Ii 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
Left 
Left 
Left 
Left 
Right 
Right 
Right 
Right 
Right 
Left 
Mean 
SD 
34 66 41 59 43 57 1.21 0.89 
30 70 37 63 44 56 1.23 0.90 
45 55 48 52 45 55 I.07 0.95 
22 78 19 81 20 80 0.86 I.04 
48 52 53 41 49 51 0.90 1.10 
50 50 45 55 47 53 1.10 0.90 
79 21 76 24 64 36 1.14 0.96 
49 51 35 65 41 59 1.28 0.71 
43 57 39 61 40 60 0.91 1.07 
44.44 55.56 43.67 56.33 43.67 56.33 1.08 0.95 
16.13 16,13 15.45 15.45 11.38 11.38 0.16 0.12 
The ventilation/perfusion ratios for the treated (t) and untreated (u) sides are given (Mean + SD, V: ventilation; V: volume; Q: 
perfusion; L: left; R: right 
Knowles et al. (13). Otherwise, the literature on this subject 
is extremely limited. In our study, ventilation/perfusion 
ratios and gas turnover were similar in the treated and 
untreated lungs. 
All patients with malignant effusion without response to 
systemic cytostatic and/or endocrine treatment, should if 
possible undergo pleurodesis, because pleurodesis provides 
for a substantially better quality of life compared to 
ongoing exudation with need for repeated evacuation of 
fluid. Pleural diseases may lead to restrictive ventilation 
impairment. Minimal pleural thickening can cause a 
reduction in unilateral ventilation that may not be 
compensated for by the contralateral lung (14). In cases 
of pleuropneumonia and empyema, one of the objectives 
with immediate treatment is to control infection, thereby 
minimizing progressive pleural thickening and pleural 
restriction in order to counteract reduction of the lung 
volume and conserve respiratory function. It would have 
been of interest to compare our results with that of patients 
who had been treated for empyema for example, but no 
such control group could be established and we are not 
aware of any such study. 
The number of patients in the present study was small. 
Out of 733 patients with large effusions only 10 finally met 
the strict inclusion criteria. Functional assessments were 
performed l-102 months after pleurodesis because seven 
patients had undergone pleurodesis long before the study 
was initiated. Of the four patients with breast carcinoma, 
three had received postoperative radiotherapy towards the 
chest wall. The only patient with Morbus Hodgkin (no. 1) 
was treated with chemotherapy and Mantel radiotherapy. 
Previous observations have shown that local and/or loco- 
regional radiotherapy to the chest wall impairs lung 
function (15,16), but the results obtained in our patients 
did not show strikingly abnormal values. This may be 
partly due to the relatively long duration between radiation 
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FIG 2. Washout time (TiJ for xenon in 9 patients after 
successful one-sided pleurodesis. Each patient is 
represented with identical symbols for the treated/ 
untreated pleura. The dotted line represents the highest 
normal value. 
and pleurodesis and the functional tests. Thus any,,under- 
lying acute inflaqatory process in the lung parenchyma 
and the pleura would have subsided. Two of the patients 
(no. 5 and no. 7) only performed dynamic spirometry, 
hence the missing values for residual volume (RV) and total 
lung capacity (TLC), However, their vital capacities (VC) 
of 101 and 82% of predicted respectively did not indicate a 
restrictive ventilation impairment. 
The two parameters used to describe lung function by 
radiospirometry were ventilation/perfusion (V/Q) ratios 
and the wash-out time for 50% of Xenon gas from the lung, 
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(Ti,*). The V/Q ratio indicates how well ventilation and 
perfusion are matched within the lungs, a value of 1.1 f 0.1 
indicating normal lung function (11). The wash-out time is 
a measure of gas turnover in the lungs. A value for Ti,z less 
than 30 set is considered normal and longer time indicates 
an increasing degree of obstructive and restrictive lung 
disease (11). In two patients (patients no. 1 and 5) the 
wash-out times were slightly above the normal limit (30 set) 
for both of their lungs. Patient no. 1 was an ex-smoker and 
patient no. 5 was a smoker. Assessment of regional lung 
function in patients with pleural disease can be complicated 
by the presence of a non-uniform thickening of the pleura. 
Emission from all radioisotopes is attenuated in tissue. For 
99mT~ and 33Xe the attenuations are approximately 
12%cn-’ (12% per cm) and 16%cm-’ (16% per cm), 
respectively (17,18). When regional differences in distribu- 
tion are expressed as a percentage of the total activity 
registered, activity in the treated lung will be under- 
estimated in proportion to the pleural thickening. Since 
pleural thickness could not be estimated more than semi- 
quantitatively by the CT-scan, only a crude correction 
could be made for tissue attenuation and consequently the 
differences observed between the treated and untreated 
lungs in terms of percentage uptake were less than precise. 
The results expressed in terms of V/Q and wash-out times 
are to a large extent independent of attenuation and, 
therefore, a better method for comparing function in the 
treated and untreated lungs. 
The adequate increase in arterial oxygen tension during 
and after exercise, without signs of alveolar hypoventilation 
further corroborates that neither any significant ventilation/ 
perfusion imbalance nor any major diffusion limitations 
were at hand. 
To the best of our knowledge, there are no previous 
studies on the influence of pleurodesis on respiratory 
function in malignant disease, illustrating that pleural 
effusion is often (except in cases of mesothelioma) a late 
manifestation with poor prognosis, even when effusion is 
the first sign of malignancy. _ 
Conclusion, 
In conclusion, this study shows that successful pleurodesis 
does not compromise the lung function. 
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